Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc covers the period ending February 22, 2023. The report primarily disseminates a press release regarding the presentation of initial safety and activity data from the Phase 1 portion of the IMC-C103C-101 clinical trial (STRIVE) for IMC-M113V at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023). IMC-M113V is a bispecific soluble TCR therapy developed for the treatment of people living with human immunodeficiency virus (PLWH).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial updates and corporate presentation materials.
Material Changes and Clinical Data
- Trial Design: The Phase 1/2 trial evaluates IMC-M113V in HLA-A*02:01 positive PLWH on suppressive antiretroviral therapy for seven years or less.
- Safety Profile: In the single ascending dose (SAD) portion, three dose levels (1.6 mcg, 5 mcg, and 15 mcg) were evaluated. All doses were well tolerated with no serious adverse events, significant hematology/chemistry changes, cytokine release syndrome, or neurotoxicity.
- Viral Load: Plasma viral load remained suppressed throughout dosing and follow-up.
- Pharmacodynamic Activity: Transient, dose-dependent increases in serum IL6 were observed. Five out of ten participants receiving the 15-mcg dose showed a greater than four-fold rise in IL6, meeting the prespecified indicator of pharmacodynamic activity.
- Next Steps: Enrollment in the multiple ascending dose (MAD) portion has commenced, with plans to enroll up to 28 participants.
Guidance, Outlook, and Risks
Management intends to use updated corporate presentation slides reflecting CROI 2023 data in meetings with analysts and investors. The filing includes extensive forward-looking statements regarding the anticipated timing, enrollment, and outcomes of the IMC-M113V trial. Key risks identified include:
- Early clinical trial results may not predict future outcomes.
- Macroeconomic conditions, the war in Ukraine, and geopolitical tensions could impact business strategy and trial execution.
- Regulatory approval uncertainties and potential supply chain disruptions.
- Delays in patient enrollment or unexpected safety/efficacy data.
- The need for additional funding given market volatility and rising interest rates.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data on the IL6 response.
- Review the updated corporate presentation slides (Exhibit 99.2) for visual data representation.
- Monitor subsequent filings for enrollment progress in the multiple ascending dose (MAD) portion of the trial.
- Assess the company's cash runway and funding needs in light of the stated risks regarding capital market volatility.
- Track regulatory interactions regarding the expansion of indications for the approved product, KIMMTRAK.